Rituximab, an anti-CD20 monoclonal antibody; ocrelizumab, another anti-CD20 monoclonal antibody; obinutuzumab, a fully humanized anti-CD20 monoclonal antibody; and epratuzumab, a recombinant humanized anti-CD22 monoclonal antibody, have been used in lupus treatment with varied success. This evidence concerns the gene CD22 and systemic lupus erythematosus.